HOME >> BIOLOGY >> NEWS
Six reporters named to receive 2002 AAAS Science Journalism Awards

A broadcast program on "18 Ways to Make a Baby," an expose on burning coal fires, and feature coverage of research that draws a line between bird songs and neurodegenerative disease, are among the entries named to win 2002 AAAS Science Journalism Awards.

Sponsored by The Whitaker Foundation, the AAAS Science Journalism Awards program, informally known as the "AAAS pinnacle of excellence prize," represents the ultimate achievement in the field of science reporting. Six reporters were named to receive AAAS Science Journalism Awards this year, recognizing exemplary communications efforts, completed between July 1, 2001 and June 30, 2002, on behalf of large and small newspapers, magazines, television, radio, and online media outlets.

"With scientists and journalists as judges, this award is a double honor and doubly humbling," said Peter N. Spotts, science and technology correspondent for The Christian Science Monitor in Boston and this year's winner for smaller newspapers. "I also feel a bit like the kid who brings home his first straight-A report card. His parents say, 'We knew you could do it. Now, keep it up!' The award poses a similar challenge to all its recipients: to hit that level of excellence with greater consistency.

The 2002 AAAS Science Journalism Award recipients, below, will each receive a $2,500 cash award and plaque during a gala reception at the 2003 AAAS Annual Meeting in Denver next February. (See www.aaas.org to register for the Annual Meeting):

Newspapers with a circulation of more than 100,000

    Andrew C. Revkin of The New York Times was honored for three articles: "U.S. Sees Problems in Climate Change" (June 3, 2002); "Sunken Fires Menace Land and Climate" (January 15, 2002); and "The Devil is in the Details" (July 3, 2001). "Fires are burning in thousands of underground coal seams from Pennsylvania to Mongolia, releases toxic gases, adding millions of tons of hea
    '"/>



Contact: Monica Amarelo
mamarelo@aaas.org
202-326-6431
American Association for the Advancement of Science
13-Nov-2002


Page: 1 2 3 4 5

Related biology news :

1. Ten Chinese reporters receive AAAS Fellowships
2. Six reporters reach the pinnacle of excellence
3. 2003 ASM Communications Award goes to Milwaukee Journal Sentinel reporters
4. Untreatable bacteria lace food supply -- top scientists to brief reporters on causes, cures to antibiotic resistance
5. UCSF scientist Joe Derisi named MaCarthur Fellow
6. DuPont scientist named one of the worlds top young innovators by MITs Technology Review Magazine
7. UGA named recipient of $5.6 million grant from NSF for corn improvement
8. USC researcher named General Motors Cancer Research Scholar
9. Device that rapidly detects nerve agents named one of greatest army inventions for 2003
10. Fox Chase Cancer Centers Alfred Knudson Jr. named 2004 Kyoto Prize winner
11. Four tourist destinations named best worldwide

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Six reporters named receive AAAS Science Journalism Awards

(Date:7/21/2015)... , July 21, 2015 Today, ZTE ... Already received as well as expected revenues in 2015 that relate ... FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... FPC1 02 5 for Axon , ...
(Date:7/13/2015)... , July 13, 2015 Synaptics ... of human interface solutions, today announced sampling of ... and display driver integration (TDDI) product targeting smartphones ... first to combine Synaptics , best-in-class touch ... display driver technology developed in the company,s Japan ...
(Date:7/9/2015)...  Unchained Labs just can,t get enough biologics ... Nano. Avid Nano designs, develops and manufactures highly ... Also today, Unchained Labs UNcaged the pUNk, ... protein sizing system. The pUNk is a high-performance ... size distribution, aggregation population and molecular weight. Its ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
(Date:7/28/2015)... ... ... VetStem Biopharma will be offering weekly private guided tours of our new ... The tour and course will be given every Wednesday at 6pm to local interested ... members are welcome to attend with their veterinarian as well. Participants will be able ...
(Date:7/28/2015)... 28, 2015 Tauriga Sciences, Inc. (OTCQB:  TAUG) ... company, today announced that its stockholders approved an increase ... of the Company from 1,000,000,000 to 2,500,000,000 at its ... at the Law Offices of Nixon Peabody LLP in ... there were 480,655,929 shares of common stock represented either ...
(Date:7/28/2015)... , July 28, 2015  Moerae Matrix ... Phase 1 clinical trial with MMI-0100, a first-in-class ... being developed for pulmonary disorders characterized by inflammation ... United Kingdom , is a double-blind, ... evaluating the safety and tolerability of MMI-0100 when ...
(Date:7/28/2015)... , July 28, 2015 CSL Behring ... Administration has accepted for review the company,s Biologics License ... single-chain (rVIII-SingleChain) for the treatment of hemophilia A. In ... Hemophilia A is a ... VIII; nearly all affected patients are male. People with ...
Breaking Biology Technology:VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3
Cached News: